Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 2:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 224 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Deep Venous Thrombosis Clear all
Completed Not applicable Interventional

Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism

NCT00413504
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Fondaparinux
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2009 · Synced Oct 3, 2026, 2:10 PM EDT
Recruiting Phase 3 Interventional

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

NCT07213778
View directory record Official record
Conditions
Symptomatic Venous Thromboembolism (VTE)
Interventions
REGN7508, Acetylsalicylic Acid (ASA), Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
La Mesa, California • Rancho Mirage, California • Riverside, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 3, 2026, 2:10 PM EDT
Completed Not applicable Interventional Results available

Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)

NCT00358735
View directory record Official record
Conditions
Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE), Bleeding
Interventions
ActiveCare CECT device, Enoxaparin
Device · Drug
Lead sponsor
Medical Compression Systems
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
La Jolla, California • Loma Linda, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Oct 3, 2026, 2:10 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Low-Molecular-Weight Heparin (LMWH) for Deep Venous Thrombosis (DVT) Prophylaxis

NCT01029821
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Low-Molecular-Weight Heparin
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 3, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

NCT00643201
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Enoxaparin, warfarin, Placebo for apixaban, Placebo for enoxaparin, Placebo for warfarin, apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
73
States / cities
Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 3, 2026, 2:10 PM EDT
Completed No phase listed Observational

Risk Factors for Venous Thromboembolism in the Community

NCT00011180
View directory record Official record
Conditions
Cardiovascular Diseases, Thromboembolism
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 3, 2026, 2:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Preliminary Clinical Usability Study for the Recovery Force DVT II Cuff

NCT03328624
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Thrombosis
Interventions
Deep Vein Thrombosis (DVT) Cuff
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 3, 2026, 2:10 PM EDT
Terminated Not applicable Interventional Results available

Angel® Catheter Early Feasibility Clinical Study

NCT01847196
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
Interventions
Angel® Catheter
Device
Lead sponsor
BiO2 Medical
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Jackson, Mississippi • Portland, Oregon • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 3, 2026, 2:10 PM EDT
Completed Not applicable Interventional

Treatment Trial for Post-Thrombotic Syndrome

NCT00633971
View directory record Official record
Conditions
Post Thrombotic Syndrome
Interventions
complex lymphedema therapy
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 3, 2026, 2:10 PM EDT
Not yet recruiting Phase 4 Interventional

Second Line Endovascular Treatment in Acute DVT

NCT06486181
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Thrombolysis/Thrombectomy
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 3, 2026, 2:10 PM EDT
Completed Not applicable Interventional

Multimodal DVT Protocol in Tourniquet-less Total Knee Arthroplasty

NCT02102828
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
extended compression, Aspirin
Device · Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 3, 2026, 2:10 PM EDT
Completed Phase 1 Interventional Results available

Delayed Versus Early Enoxaparin Prophylaxis After Traumatic Brain Injury (TBI)

NCT01014403
View directory record Official record
Conditions
Venous Thromboembolism, Traumatic Brain Injury
Interventions
enoxaparin, placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Dallas, Texas • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 3, 2026, 2:10 PM EDT
Completed Not applicable Interventional Results available

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

NCT02744092
View directory record Official record
Conditions
Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
Interventions
Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Warfarin, Dalteparin, Enoxaparin, Fondaparinux
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
151
States / cities
Chula Vista, California • Fremont, California • Fresno, California + 104 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 3, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE

NCT00558259
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
dabigatran etexilate 150 mg twice daily (BID), matching placebo twice daily (BID)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
21
States / cities
Birmingham, Alabama • Huntsville, Alabama • Laguna Hills, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 3, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

NCT01662908
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Thrombosis
Interventions
edoxaban tosylate, enoxaparin/unfractionated heparin, warfarin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
29
States / cities
Dothan, Alabama • Montgomery, Alabama • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 3, 2026, 2:10 PM EDT
Recruiting Phase 3 Interventional

The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

NCT06861088
View directory record Official record
Conditions
Venous Thromboembolism, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
Interventions
Kinisoquin™, Placebo
Drug
Lead sponsor
Quercis Pharma AG
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Ventura, California • Miami Lakes, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 3, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

NCT00439777
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin overlapping with and followed by VKA
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
4,833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
23
States / cities
Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 3, 2026, 2:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating the Relationship Between Blood Clotting Disorders, Inflammation, and Obesity in Individuals With Venous Disorders and Post-Thrombotic Syndrome

NCT00395265
View directory record Official record
Conditions
Venous Thrombosis, Venous Insufficiency
Interventions
Not listed
Lead sponsor
University of Vermont
Other
Eligibility
40 Years to 79 Years
Enrollment
2,211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Oct 3, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

NCT00633893
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
2,711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
87
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 3, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

NCT00571649
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Rivaroxaban placebo, Enoxaparin placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
8,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
121
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 3, 2026, 2:10 PM EDT
Not listed Not applicable Interventional

Whole-leg Ultrasound in Pregnant Patients

NCT01319474
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Whole-leg compression ultrasound
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 3, 2026, 2:10 PM EDT
Completed No phase listed Observational

Sonography Outcomes Assessment Program for Lower Extremity Deep Venous Thrombosis

NCT00178789
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2007 · Synced Oct 3, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Odiparcil For The Prevention Of Venous Thromboembolism

NCT00244725
View directory record Official record
Conditions
Deep Vein Thrombosis, Fibrillation, Atrial, Venous Thromboembolism, Pulmonary Embolism
Interventions
Odiparcil, Warfarin, Coumadin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
35 Years and older
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
46
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 3, 2026, 2:10 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy

NCT00539942
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Arixtra (fondaparinux sodium), Intermittent compression devices (ICD)
Drug · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 85 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 3, 2026, 2:10 PM EDT